---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-115351"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:30:28.990027+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rezolute Q1 FY2025 net loss $15.4M; cash $117.8M; Phase 3 on track

## Summary
- Net loss $15.4M vs $14.5M YoY; R&D $12.8M, G&A $4.2M.
- Cash, equivalents, marketable securities $117.8M (Sep 30) vs $127.1M (Jun 30).
- Phase 3 sunRIZE congenital HI enrollment on track; U.S. enrollment expected early 2025.
- Tumor HI Phase 3 enrollment expected H1 2025; topline results H2 2026.
- Topline sunRIZE results expected in second half of 2025.

## SEC filing metadata
- accession: 0001104659-24-115351
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465924115351/0001104659-24-115351-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465924115351/tm2427368d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-115351
- JSON: https://secwatch.observer/filing/0001104659-24-115351.json
- Plain text: https://secwatch.observer/filing/0001104659-24-115351.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.